ATE388165T1 - Menschliches cnp-gen und vorläuferprotein - Google Patents

Menschliches cnp-gen und vorläuferprotein

Info

Publication number
ATE388165T1
ATE388165T1 AT96114549T AT96114549T ATE388165T1 AT E388165 T1 ATE388165 T1 AT E388165T1 AT 96114549 T AT96114549 T AT 96114549T AT 96114549 T AT96114549 T AT 96114549T AT E388165 T1 ATE388165 T1 AT E388165T1
Authority
AT
Austria
Prior art keywords
precussion
protein
human cnp
human
cnp gene
Prior art date
Application number
AT96114549T
Other languages
English (en)
Inventor
Shoji Tanaka
Kayoko Kawashima
Yasunori Tawaragi
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Asubio Pharma Co Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd, Hisayuki Matsuo filed Critical Asubio Pharma Co Ltd
Application granted granted Critical
Publication of ATE388165T1 publication Critical patent/ATE388165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96114549T 1990-09-27 1991-09-27 Menschliches cnp-gen und vorläuferprotein ATE388165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトｃｎｐ遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
ATE388165T1 true ATE388165T1 (de) 2008-03-15

Family

ID=17337688

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91116557T ATE162532T1 (de) 1990-09-27 1991-09-27 Merschliches cnp-gen und vorläufer protein
AT96114549T ATE388165T1 (de) 1990-09-27 1991-09-27 Menschliches cnp-gen und vorläuferprotein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT91116557T ATE162532T1 (de) 1990-09-27 1991-09-27 Merschliches cnp-gen und vorläufer protein

Country Status (8)

Country Link
US (1) US6034231A (de)
EP (2) EP0477971B1 (de)
JP (1) JP3026354B2 (de)
AT (2) ATE162532T1 (de)
DE (2) DE69128754T2 (de)
DK (1) DK0477971T3 (de)
ES (2) ES2302333T3 (de)
GR (1) GR3026554T3 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
EP1569683B1 (de) 2002-11-26 2010-03-03 Biocon Limited Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP3620530A1 (de) 2004-03-31 2020-03-11 Kazuwa Nakao Zusammensetzung zur erhöhung der körpergrösse
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US20070184466A1 (en) * 2005-11-18 2007-08-09 The Brigham And Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective endothelium
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
HRP20160303T1 (hr) * 2008-05-23 2016-04-22 Daiichi Sankyo Company, Limited Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN114796460A (zh) 2015-07-30 2022-07-29 生物马林药物股份有限公司 C型利尿钠肽变体在治疗骨骼发育不良中的用途
EP3337894A1 (de) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Herstellung von alkalischen phosphatasen
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
WO2021055497A1 (en) 2019-09-16 2021-03-25 Biomarin Pharmaceutical Inc. Cnp variants and conjugates thereof
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
WO2023108005A1 (en) 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
TW202513806A (zh) 2023-06-07 2025-04-01 美商拜奧馬林製藥公司 高通量篩選與身材矮小相關之基因變異體
WO2025101863A1 (en) 2023-11-08 2025-05-15 Biomarin Pharmaceutical Inc. Cnp variants, conjugates and formulations thereof
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JP3026354B2 (ja) 2000-03-27
GR3026554T3 (en) 1998-07-31
EP0769554B1 (de) 2008-03-05
JPH04139199A (ja) 1992-05-13
ATE162532T1 (de) 1998-02-15
ES2302333T3 (es) 2008-07-01
EP0477971A2 (de) 1992-04-01
DE69133593D1 (de) 2008-04-17
EP0769554A2 (de) 1997-04-23
US6034231A (en) 2000-03-07
EP0477971B1 (de) 1998-01-21
ES2113865T3 (es) 1998-05-16
EP0769554A3 (de) 1997-05-28
DE69128754T2 (de) 1998-06-04
DE69133593T2 (de) 2009-04-02
DE69128754D1 (de) 1998-02-26
DK0477971T3 (da) 1998-09-21
EP0477971A3 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
IL131016A0 (en) Selection of proteins using rna-protein fusions
DE69131699D1 (de) Verändertes menschliches iL-6
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
NO971875L (no) Cathepsin 02 protease
ES2184728T3 (es) Proteinas de union a la fibronectina.
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
HU906270D0 (en) Anticoagulant peptides
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
IL92551A0 (en) Anticoagulant peptides
EP0723016A3 (de) Leukocyten-aktivierender Faktor
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
AU8957091A (en) Immunoglobulin-binding proteins and recombinant dna molecules coding therefor
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
FI944997L (fi) Parannettu rekombinantti-proteiinien tuotanto
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.
ATA166890A (de) Rekombinantes dna-molekül für allergene des erlenpollens, damit hergestellte proteine bzw. polypeptide, sowie deren anwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties